Clinical trial
Valsartan/Hydrochlorothiazide Combination in the Treatment of Severe…
NCT00273299 · Novartis, Industry · Completed
Key facts
| NCT number | NCT00273299 |
|---|---|
| Title | Valsartan/Hydrochlorothiazide Combination in the Treatment of Severe Hypertension |
| Official title | A 6-Week Study to Evaluate the Combination of Valsartan/HCTZ (160/12.5mg With Forced Titration to Maximum Dose of 320/25mg) Compared to Valsartan Monotherapy (160mg With Forced Titration to 320mg) as Initial Therapy in Patients With Severe Hypertension |
| Lead sponsor | Novartis, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Hypertension |
| Intervention type | Drug |
| Interventions | valsartan plus hydrochlorothiazide |
| Enrollment | 607 |
| Start date | Nov 1, 2005 |
| Primary completion | Jul 1, 2006 |
| Completion | Jul 1, 2006 |
| First posted | Jan 9, 2006 |
| Last update posted | Nov 8, 2011 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: